collagen type iii alpha 1 chain col3a1  (Proteintech)

Journal: The Tohoku Journal of Experimental Medicine

Article Title: JMJD3 is Involved in Intracranial Aneurysm Development by Regulating DLX2 Expression through H3K27me3 Modification

doi: 10.1620/tjem.2023.j048

Figure Lengend Snippet: Fig. 2. Silencing of DLX2 governs the proliferation and apoptosis of HA-VSMC. (A) The silencing efficiency of shRNAs targeting DLX2 by RT-qPCR (n = 3). (B) The proliferation of HA-VSMC was examined using EdU (n = 3). (C) Detection of apoptosis of HA-VSMC by flow cytometry (n = 3). (D) Detection of COL1A1, COL3A1, MMP2 and MMP9 in HA-VSMC by western blot (n = 3). *p < 0.05 vs. the sh-NC group. The measurement data were expressed as mean ± SD. Unpaired t-test was performed for comparisons between two groups, one-way or two-way ANOVA was used for comparisons among multiple groups, and Tukey’s post hoc test was applied for pairwise comparisons. sh-NC, short hairpin RNA (shRNA) targeting negative control; sh-DLX2, short hairpin RNA (shRNA) targeting DLX2.

Article Snippet: The membranes were blocked at room temperature with Tris-buffered saline-Tween 20 containing 5% bovine serum albumin (BSA) and incubated with diluted primary antibodies against rabbit antibodies to DLX2 (ab272902, Abcam), JMJD3 (ab169197, Abcam), collagen type I alpha 1 chain (COL1A1) (#91144, Cell Signaling Technologies, Beverly, MA, USA), collagen type III alpha 1 chain (COL3A1) (sc-271249, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), matrix metalloproteinase-2 (MMP-2) (ab181286, Abcam), matrix metalloproteinase-9 (MMP9) (ab76003, Abcam), H3K27me3 (#9733, Cell Signaling Technologies), and GAPDH (ab9485, Abcam) overnight at 4°C and with the secondary antibody goat anti-rabbit IgG antibody (ab6721, Abcam) or rabbit anti-mouse IgG antibody (ab6728, Abcam) at room temperature.

Techniques: Quantitative RT-PCR, Flow Cytometry, Western Blot, shRNA, Negative Control

Journal: The Tohoku Journal of Experimental Medicine

Article Title: JMJD3 is Involved in Intracranial Aneurysm Development by Regulating DLX2 Expression through H3K27me3 Modification

doi: 10.1620/tjem.2023.j048

Figure Lengend Snippet: Fig. 5. Silencing of JMJD3 inhibits the formation of intracranial aneurysm. Rats with intracranial aneurysm were administered with sh-DLX2 or sh-JMJD3 alone, or with oe-DLX2. Model, successfully modeled intracranial aneurysm rats. (A) Detection of COL1A1, COL3A1, DLX2, and JMJD3 in the artery of intracranial aneurysm rat by western blot (n = 8). (B) The blood pressure of rats in each group (n = 8). (C) Histopathological changes of arteries in rats with intracranial aneurysm detected by HE staining (n = 8). (D) The levels of inflammatory factors TNF-α, IL-1β, and IL-6 in the tail vein blood of rats by ELISA (n = 8). *p < 0.05 vs. the sham group; #p < 0.05 vs. the sh-NC group; &p < 0.05 vs. the sh-JMJD3 + oe-NC group. The measurement data were expressed as mean ± standard deviation. Two-way ANOVA was used for comparisons among multiple groups and Tukey’s post hoc test was used for pairwise comparisons.

Article Snippet: The membranes were blocked at room temperature with Tris-buffered saline-Tween 20 containing 5% bovine serum albumin (BSA) and incubated with diluted primary antibodies against rabbit antibodies to DLX2 (ab272902, Abcam), JMJD3 (ab169197, Abcam), collagen type I alpha 1 chain (COL1A1) (#91144, Cell Signaling Technologies, Beverly, MA, USA), collagen type III alpha 1 chain (COL3A1) (sc-271249, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), matrix metalloproteinase-2 (MMP-2) (ab181286, Abcam), matrix metalloproteinase-9 (MMP9) (ab76003, Abcam), H3K27me3 (#9733, Cell Signaling Technologies), and GAPDH (ab9485, Abcam) overnight at 4°C and with the secondary antibody goat anti-rabbit IgG antibody (ab6721, Abcam) or rabbit anti-mouse IgG antibody (ab6728, Abcam) at room temperature.

Techniques: Western Blot, Staining, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: BMC Cancer

Article Title: Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression

doi: 10.1186/s12885-022-09670-6

Figure Lengend Snippet: Primer sequences used for qRT-PCR analysis

Article Snippet: Those procured from Santa Cruz Biotechnology, USA were used at 1:250 dilution, which included anti-Collagen type III Alpha 1 chain/COL3A1 (Cat no. sc-514601), anti-Regulator of G-protein signalling 2/RGS2 (Cat no. sc-100761) and anti-Occludin/OCLN (Cat no. sc-133256). anti-Desmoplakin/DSP (Cat no. A303-355A) and anti-Junctional adhesion molecule A/F11R (Cat no. A302-891A) antibodies were from Bethyl lab, USA.

Techniques: Sequencing

Journal: BMC Cancer

Article Title: Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression

doi: 10.1186/s12885-022-09670-6

Figure Lengend Snippet: NOSTRIN-induced alteration of transcripts associated with epithelial mesenchymal transition in HCT116 cells

Article Snippet: Those procured from Santa Cruz Biotechnology, USA were used at 1:250 dilution, which included anti-Collagen type III Alpha 1 chain/COL3A1 (Cat no. sc-514601), anti-Regulator of G-protein signalling 2/RGS2 (Cat no. sc-100761) and anti-Occludin/OCLN (Cat no. sc-133256). anti-Desmoplakin/DSP (Cat no. A303-355A) and anti-Junctional adhesion molecule A/F11R (Cat no. A302-891A) antibodies were from Bethyl lab, USA.

Techniques: Binding Assay